Clinical Characteristics and Prognosis of Patients with Primary Bone Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2021.05.022
- Author:
You-Fan FENG
1
;
Xiao-Fang WEI
2
;
Qi-Ke ZHANG
3
;
Li ZHAO
4
,
5
;
Xiao-Qin LIANG
6
;
Yuan FU
2
;
Xiu-Juan HUANG
2
;
Qing-Fen LI
2
Author Information
1. Department of Hematology, Gansu Provincial Hospital,Lanzhou 730000, Gansu Province, China,The First Clinical Medical College of Lanzhou University,Lanzhou 730000, Gansu Province, China.
2. Department of Hematology, Gansu Provincial Hospital,Lanzhou 730000, Gansu Province, China.
3. Department of Hematology, Gansu Provincial Hospital,Lanzhou 730000, Gansu Province, China,E-mail: zqk05@ 163.com.
4. The First Clinical Medical College of Lanzhou University,Lanzhou 730000, Gansu Province, China,Gansu Key Laboratory of Genetic Study of Hematopathy
5. Lanzhou 730000, Gansu Province, China,E-mail: zhaoli@lzu.edu.cn.
6. Department of Pathology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
- Publication Type:Journal Article
- MeSH:
Aged;
Aged, 80 and over;
Female;
Humans;
Lymphoma, Large B-Cell, Diffuse;
Male;
Middle Aged;
Prognosis;
Remission Induction;
Retrospective Studies;
Rituximab
- From:
Journal of Experimental Hematology
2021;29(5):1517-1521
- CountryChina
- Language:Chinese
-
Abstract:
METHODS:The clinical data of 15 patients with primary diffuse large B-cell lymphoma treated in our hospital from January 2013 to December 2020 were collected, the clinical data and prognosis of the patients were analyzed retrospectively.
RESULTS:The median age of the 15 patients was 59 (19-89) years old; among the patients, 7 were males and 8 were females, ostealgia was the initial symptom. The pathological types of the 15 patients were diffuse large B-cell lymphoma (DLBCL), 5 cases of Has type GCB subtype (5/15), and 10 cases of Non-GCB subtype (10/15). After 15 patients were diagnosed, 11 patients (11/15) received chemotherapy, 3 patients (3/15) received surgery, and 1 patient was untreated (1/15), median chemotherapy courses was 5 (1-9). 8 patients have achieved complete remission (8/15), 3 patients achieved partial remission (3/15), and 1 patient achieved stable disease (1/15), 1 patient was lost to follow-up (1/15), 1 patient was untreated (1/15), and 1 patient was progression of disease (1/15). Age, pathological subtype, sex, stage, β2-MG level, LDH level, and the using of rituximab were not correlated with the complete remission rate of the patients(P>0.05), while the IPI score was correlated with the recent complete remission rate (P<0.05). The median follow-up time was 19 (1-38) months, 10 patients survived, in which 6 cases were still in complete remission, and the median time to progression-free survival was 15 (1-38) months.
CONCLUSION:The first symptom of primary bone diffuse large B-cell lymphoma is bone pain, the main pathological subtype is Non-GCB, the optimal treatment is combined chemotherapy, and the IPI score is related to the prognosis of the treatment.
